Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Science (New York, N.Y.) · 2022
    MBMichael BergerLELukas Edward DowJMJuan Miguel MosqueraHBHimisha Beltran+4 more →EKEkta Khurana
    PMID: 35617398PMCID: PMC9299269DOISenior author229 citations
  2. 2
    Genome biology · 2020
    EKEkta Khurana
    PMID: 32216817PMCID: PMC7098089DOISenior author54 citations
  3. 3
    Cell systems · 2024
    EKEkta Khurana
    PMID: 39236711PMCID: PMC11415227DOISenior author7 citations

Publications

79 publications

Funding

15 grantsView NIH portfolio on RePORTER ↗

Active

6 grants
  • MPI
    Identifying and Targeting 3D Regulatory Nodes that Maintain Glioblastoma Programs
    National Institute of Neurological Disorders and Stroke · 2024–2029
    R01NS136475-03
  • PI
    Computational and experimental methods for scalable identification of oncogenic non-coding regions
    National Cancer Institute · 2018–2029· 4 renewals
    R01CA218668-08
  • PI
    Predicting off-target resistance to androgen receptor signaling inhibitors from histology slides using foundation models
    Prostate Cancer Foundation · 2026–2028
    PCF 252114-01
  • PI
    Clinical identification and targeting of non-neuroendocrine lineage plasticity in castration-resistant prostate cancer
    U.S. Department of Defense · 2023–2027
    HT9425-23-1-0074
  • PI
    Prostate cancer non-neuroendocrine lineage plasticity: detection using multimodal integration and immunotherapeutic targeting
    Starr Cancer Consortium · 2024–2026
    I17-0132
  • Co-I
    The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
    National Cancer Institute · 2021–2026
    U24CA264032-05
Completed grants (9)
  • Co-I
    Elucidating the Role of MALAT1 Somatic Driver Mutations in Colorectal Cancer
    National Cancer Institute · 2018–2024
    R01CA227722-01A1
  • Co-I
    (PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
    National Cancer Institute · 2018–2024
    R01CA231283-01
  • MPI
    The Joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
    National Cancer Institute · 2016–2023
    U24CA210989-05
  • MPI
    MSK SPORE in Genomic Instability in Breast Cancer
    National Cancer Institute · 2020–2022 · via Memorial Sloan Kettering Cancer Center
    P50CA247749-02
  • Sub-PI
    Student Support - Tri-Institutional PhD in Computational Biology & Medicine
    National Institute of Neurological Disorders and Stroke · 2021–2022 · via Cornell University - Ithaca
    No publications yet
    U19NS104653-02
  • PI
    dbgap Project #21894 : Development of new clustering method to identify molecular signatures for drug-resistant patients
    Database of Genotypes and Phenotypes · 2020–2021
    No publications yet
    DBGAP 203914-01
  • Sub-PI
    Collaborative Research: Uncovering how riboswitches exploit out-of-equilibrium RNA folding pathways to make genetic decisions (Subaward)
    National Science Foundation · 2020–2020 · via Northwestern University
    PHY-1914567
  • KP
    Epigenetic Characterization of Germline Familial Multiple Myeloma Risk Genes - Admin Supplement
    National Cancer Institute · 2016–2017
    4 R01 CA167824-05 (A
  • KP
    Prioritizing Rare, Non-Coding Variants Associated With Cancer Using Functional Annotation
    National Human Genome Research Institute · 2016–2017 · via Yale University
    R01HG008126-01A1

Honors & distinctions

1 honor
  • PECASE (Presidential Early Career Award) · U.S. Government (PECASE)

Clinical research

1 study

Active

1 study
  • PI
    Computational and experimental methods for scalable identification of oncogenic non-coding regions
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)

News mentions

10 mentionsView all WCM news ↗
Show 5 more mentions
  • Dr. Ekta Khurana Receives Grant to Study Prostate Cancer Evolution
    March 22, 2023

    Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy.

  • A New Tool for Discovering Cancer-Driving Structural Variations
    September 26, 2022

    An advanced software tool for analyzing DNA sequences from tumor samples has uncovered likely new cancer-driving genes, in a study led by Weill Cornell Medicine researchers.

  • New Cancer Subtype May Illuminate Treatment Strategy
    May 27, 2022

    Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.

  • Most Comprehensive Whole-Genome Cancer Study To Date Catalogs Tumor-Driving Mutations
    February 7, 2020

    The scope of the DNA changes that drive cancers has been illuminated as never before in a set of studies by a large international scientific team including Weill Cornell Medicine researchers. In six studies published Feb. 5 in Nature, and 18 papers in other Nature-affiliated journals, this scientific consortium reported the results from analyses of DNA from more than 2,600 biopsied tumor samples across 38 different types of cancer.

  • Awards and Honors Across Weill Cornell Medicine - July 31, 2019
    July 31, 2019

    Awards, honors, prizes and achievements for the month of July.

Mentoring

22 menteesAll publications with mentees →
1 MD student · 6 PhD students · 6 Postdocs · 9 other

External relationships

Professional Services

National Institutes of Health · Prostate Cancer Foundation